Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
Views & Analysis Will pharma get its own Brexit deal? After the Nissan deal, pharma is looking for similar reassurances
News UK drug discovery evolving - and facing up to Brexit A new UK report confirms the shift in pharma R&D spending from in-house teams to greater use of outsourcing and in-licensing - but also warns that investment in drug discovery in the co
Views & Analysis England’s ‘world-first’ cancer database – can it deliver on ... The world's first national database of cancer treatment outcomes has been launched in England.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
